- Subjects must have recurrent or persistent endometrial carcinoma (including:
Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma,
dedifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma,
adenocarcinoma not otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous
cell carcinoma, and transitional cell carcinoma) or endometrial carcinosarcoma).
Histologic documentation of diagnosis of carcinoma is required.
- All patients must have measurable disease. Measurable disease is defined by RECIST
(version 1.1). Measurable disease is defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded). Each
lesion must be ≥ 10 mm when measured by CT, MRI or caliper measurement by clinical
exam; or ≥ 20 mm when measured by chest x-ray. Lymph nodes must be ≥ 15 mm in short
axis when measured by CT or MRI.
- Patients must have at least one "target lesion" to be used to assess response on this
protocol as defined by RECIST version 1.1 (Section 12.0). Tumors within a previously
irradiated field will be designated as "non-target" lesions unless progression is
documented, or a biopsy is obtained to confirm persistence at least 90 days following
completion of radiation therapy.
- Females, age ≥ 18 years and life expectancy of ≥ 12 weeks.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Resolution of (non-laboratory) adverse effects of recent surgery, radiotherapy, or
chemotherapy to Grade ≤1 prior to first study treatment (with the exception of
alopecia or neuropathy).
- Patients must have had one prior platinum-based chemotherapeutic regimen for
management of endometrial carcinoma or carcinosarcoma. Initial treatment may include
chemotherapy, chemotherapy and radiation therapy, and/or consolidation/maintenance
therapy. Chemotherapy administered in conjunction with primary radiation as a
radiosensitizer WILL be counted as a systemic chemotherapy regimen.
- Patients are allowed to have up to three prior cytotoxic regimens for management of
recurrent or persistent disease. Hormonal therapies will not count toward the prior
- Adequate normal organ and marrow function defined by the following laboratory results
obtained within 14 days prior to first treatment:
- Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (> 1500 per mm^3)
- Platelet ≥ 75 x 10^9/L (>100,000 per mm^3)
- Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN). (Unless
Gilbert's Syndrome, for which Bilirubin ≤ 3 x institutional upper limit of normal
(ULN), without concurrent clinically significant liver disease)
- AST (SGOT)/ALT (SGPT) ≤ 3 x institutional upper limit of normal (ULN) unless
liver metastases are present, in which case it must be ≤ 5x ULN
- Serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN)
- Female subjects must either be of non-reproductive potential (i.e., post-menopausal by
history: ≥60 years old and no menses for ≥1 year without an alternative medical cause
and confirmed by FSH levels; OR history of hysterectomy, OR history of bilateral tubal
ligation, OR history of bilateral oophorectomy) or must have a negative serum
pregnancy test upon study entry.
- Archival tissue, 15-20 unstained PPFE slides, must be available. If archival tissue is
not available, patient will be required to undergo.
- Subject is willing and able to comply with the protocol for the duration of the study
including undergoing treatment, procedures (including on-treatment biopsy), and
scheduled visits and examinations including follow up.
- Patients must have been enrolled or agree to consent to the companion genomic
profiling study MSKCC IRB# 12-245, to determine microsatellite stability, MSS vs MSI.
- Patients must have signed an approved informed consent and authorization permitting
release of personal information.
- Women of childbearing potential (WOCBP) must agree to follow instructions for
method(s) of contraception (See IDO Appendix 1) for the duration of treatment with
study treatment(s) plus 5 months post-treatment completion.
- Involvement in the planning and/or conduct of the study (applies to both Bristol-Myers
Squibb staff and/or staff at the study site);
- MSI-H and MMR-deficient patients will be excluded.
- Prior enrollment in the present study or another clinical study with receipt of an
investigational product during the last 4 weeks.
- Any previous treatment with an IDO, PD-1 or PD-L1 inhibitor, or any anti-CTLA4.
- History of another primary malignancy except for:
- Malignancy treated with curative intent and with no known active disease ≥3 years
before the first dose of study drug and of low potential risk for recurrence
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
- Adequately treated carcinoma in situ without evidence of disease (e.g., cervical
cancer in situ)
- Adequately treated stage 1 breast cancer.
- Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, targeted
therapy, biologic therapy, tumor embolization, radiation therapy, monoclonal
antibodies) < 21 days prior to the first dose of study drug. Receipt of the last dose
of hormonal therapy within < 7 days prior to the first dose of study drug.
- Less than 4 weeks since the patient underwent any major surgery (e.g., major:
laparotomy, laparoscopy) There is no delay in treatment for minor procedures (e.g.,
central venous access catheter placement).
- Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3
- Current or prior use of immunosuppressive medication within 28 days before the first
dose of BMS-986205 and Nivolumab, with the exceptions of intranasal and inhaled
corticosteroids or systemic corticosteroids at physiological doses, which are not to
exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Patients who have
received acute, low dose, systemic immunosuppressant medications (e.g., dexamethasone
for nausea or steroids as CT scan contrast premedication) may be enrolled.
- Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous
immunotherapy agent, or any unresolved irAE > Grade 1
- Active or prior documented autoimmune disease within the past 2 years NOTE: Subjects
with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within
the past 2 years) are not excluded.
- Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,
- History of primary immunodeficiency
- History and/or confirmed pneumonitis or interstitial lung disease requiring steroids
- History of allogeneic organ transplant
- History of hypersensitivity to nivolumab
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active
bleeding diatheses including any subject known to have evidence of acute or chronic
hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric
illness/social situations that would limit compliance with study requirements or
compromise the ability of the subject to give written informed consent
- Known history of previous clinical diagnosis of tuberculosis
- Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive
of but not limited to surgery, radiation and/or corticosteroids.
- History of leptomeningeal carcinomatosis
- Uncontrolled seizures.
- Receipt of live attenuated vaccination within 30 days prior to study entry or within
30 days of receiving BMS-986205 or nivolumab.
- Any condition that, in the opinion of the investigator, would interfere with
evaluation of study treatment or interpretation of patient safety or study results
- Patients who are pregnant or breastfeeding or patients of reproductive potential who
are not willing to employ effective birth control from screening to 5 months after the
last dose of BMS-986205 and nivolumab combination therapy
- Participants with conditions known to interfere significantly with the absorption of
oral medication, as per investigator judgement. History of small or large bowel
obstruction, perforation, bowel fistula or abscess, within 3 months of registration,
including subjects with palliative gastric drainage catheters. Subjects with
palliative diverting ileostomy or colostomy are allowed if they have been symptom free
for more than 3 months.
- Subjects with refractory ascites, defined as ascites needing drainage catheter or
therapeutic paracentesis more often than every 4 weeks.
- Participants with a personal or family (ie, in a first-degree relative) history or
presence of cytochrome b5 reductase deficiency (previously called methemoglobin
reductase deficiency) or other diseases that puts them at risk of methemoglobinemia.
- Underlying G6PD deficiency, blood methemoglobin > ULN, assessed in an arterial or
venous blood sample or by co-oximetry.
- History or presence of hypersensitivity or idiosyncratic reaction to methylene blue
- Prior history of serotonin syndrome.